| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-03-05 | DNA Therapeutics (France) Curie Cancer (France) | DT01 and Dbait-based molecules | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2014-03-04 | Harlan Contract Research Services (USA) Bertin Pharma (France) | drug discovery and translational medicine services, including expanded profiling and molecule testing | collaboration |
Technology - Services | Collaboration agreement | |
| 2014-03-04 | ProBioGen (Germany) Merus (The Netherlands) | GlymaxX® Antibody Glyco-Engineering technology | licensing |
Technology - Services | Licensing agreement | |
| 2014-03-03 | Genfit (France) Sanofi (France) | molecules that aim to correct the mitochondrial dysfunction associated with certain pathologies including metabolic diseases | R&D |
Metabolic diseases | Milestone | |
| 2014-03-03 | Cobra Biologics (UK - Sweden) BioCancell (Israel) | BC-821 | manufacturing |
Cancer - Oncology | Production agreement | |
| 2014-03-03 | Amicus Therapeutics (USA - NJ) | chief medical officer, chief operating officer | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2014-03-03 | Bind Therapeutics (USA - MA) | chief operating officer, vice president | nomination | Cancer - Oncology | Nomination | |
| 2014-03-01 | Canbex Therapeutics (UK) | chief medical officer | nomination | CNS diseases - Neurological diseases - Neurodegenerative diseases | Nomination | |
| 2014-02-28 | Discuva (UK) Roche (Switzerland) | new antibotics based on SATIN technology platform | development |
Infectious diseases | Development agreement | |
| 2014-02-28 | Esteve (Spain) RegenX Biosciences (USA - MD) | NAV rAAV9 vectors | mucopolysaccharidosis type IIIA or Sanfilippo syndrome Type A | licensing |
Rare diseases | Licensing agreement |
| 2014-02-24 | Vivalis (France) Sanofi Pasteur (France) | fully human monoclonal antibody against an additional undisclosed infectious disease target using VIVA Screen™ technology | undisclosed infectious disease | licensing |
Infectious diseases | Licensing agreement |
| 2014-02-24 | Andromeda Biotech (Israel) Teva Pharmaceutical (Israel) | DiaPep277® | type 1 diabetes | product acquisition |
Metabolic diseases | Product acquisition |
| 2014-02-24 | Cell Therapy Catapult (UK) University of Leeds (UK) | acellular scaffold technology for the delivery of cellular therapies | R&D |
Regenerative medicine - Technology -Services | R&D agreement | |
| 2014-02-24 | Celladon (USA - CA) Servier (France) | novel SERCA2b modulators | type 2 diabetes and other metabolic diseases | R&D |
Metabolic diseases | R&D agreement |
| 2014-02-24 | Plasticell (UK) JCR Pharmaceuticals (Japan) | CombiCult® | collaboration
|
Technology - Services | Collaboration agreement | |
| 2014-02-21 | Bavarian Nordic (Denmark) U.S.Department of Defense (USA) | MVA-BN vaccine platform | Burkholderia pseudomallei and Burkholderia mallei infections | R&D |
Infectious diseases | R&D agreement |
| 2014-02-21 | Nuevolution (Denmark) Merck&Co (USA -NJ) | small molecule compounds targeting an undisclosed intracellular target | licensing |
Establishment of a new subsidiary in the EU | ||
| 2014-02-20 | PPD (USA) Charité–Universitätsmedizin Berlin (Germany) | collaboration |
Clinical research agreement | |||
| 2014-02-20 | Dilafor (Sweden) Lee’s Pharmaceutical Holdings (China) | tafoxiparin | obstetrics and gynecological indications | licensing |
Women health | Licensing agreement |
| 2014-02-19 | Human Stem Cells Institute (Russia) RVC Biofund (Russia) | collaboration |
Regenerative medicine | Collaboration agreement |
